tiprankstipranks
Trending News
More News >

Recordati Approves 2024 Financials and Appoints New Board

Story Highlights
Recordati Approves 2024 Financials and Appoints New Board

Confident Investing Starts Here:

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an update.

Recordati S.p.A. announced the approval of its 2024 financial statements and a dividend increase to €1.27 per share, reflecting a 5.8% rise from the previous year. Additionally, a new Board of Directors was appointed for the 2025-2027 period, with Andrea Recordati and Robert Koremans confirmed as Chairman and CEO, respectively. The company also renewed its authorization to purchase and dispose of treasury shares and approved a new share purchase program to support stock option and performance share plans.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica S.p.A. is a pharmaceutical company based in Milan, Italy, primarily engaged in the research, development, manufacturing, and marketing of pharmaceuticals. The company focuses on specialty and primary care products and operates in a global market.

YTD Price Performance: -2.73%

Average Trading Volume: 25,406

Technical Sentiment Signal: Hold

Current Market Cap: €10.12B

For an in-depth examination of REC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App